ORA - Oxford University Research Archive

1 - 9 of 9

1

Journal article

Reduced bacterial skin infections in HIV-infected African children randomized to long-term cotrimoxazole prophylaxis

Prendergast, AJ, Bwakura-Dangarembizi, M, Mugyenyi, P, et al.
2016-11-05

2

Journal article

Improved adherence to antiretroviral therapy observed among HIV-infected children whose caregivers had positive beliefs in medicine in Sub-Saharan Africa

Abongomera, G, Cook, A, Musiime, V, et al.
2016-01-01

3

Journal article

The effect of diurnal variation, CYP2B6 genotype, and age on the pharmacokinetics of nevirapine in African Children

Bienczak, A, Cook, A, Wiesner, L, et al.
2016-10-05

4

Journal article

Abacavir, zidovudine, or stavudine as paediatric tablets for African HIV-infected children (CHAPAS-3): an open-label, parallel-group, randomised controlled trial.

Mulenga, V, Musiime, V, Kekitiinwa, A, et al.
2016-02-05

5

Journal article

Baseline inflammatory biomarkers identify subgroups of HIV-infected African children with differing responses to antiretroviral therapy

Prendergast, A, Szubert, A, Berejena, C, et al.
2016-01-01

6

Journal article

Tuberculosis incidence is high in HIV-infected African children but is reduced by co-trimoxazole and time on antiretroviral therapy.

Crook, AM, Turkova, A, Musiime, V, et al.
2016-03-23

7

Journal article

Virologic response to first-line efavirenz- or nevirapine-based antiretroviral therapy in HIV-infected African children

Kekitiinwa, A, Szubert, AJ, Spyer, M, et al.
2017-06-01

8

Journal article

Determinants of virological outcome and adverse events in African children treated with paediatric nevirapine fixed-dose-combination tablets

Bienczak, A, Denti, P, Cook, A, et al.
2017-01-01

9

Journal article

The impact of genetic polymorphisms on the pharmacokinetics of efavirenz in African children

Bienczak, A, Cook, A, Wiesner, L, et al.
2016-03-11

TO TOP